Abstract
Breast cancer is one of the commonest cancers among Algerian females. Compared to Western populations, the median age of diagnosis of breast cancer is much lower in Algeria. The objective of this study is to explore the expression of several miRNAs reported to be deregulated in breast cancer. The miRNAs miR-21, miR-125b, miR-100, miR-425-5p, miR-200c, miR-183 and miR-182 were studied on tumor and normal adjacent Algerian breast tissues using quantitative reverse transcription real time PCR, and the results were analyzed according to clinical characteristics. Compared to the normal adjacent tissues, miR-21, miR-183, miR-182, miR-425-5p and miR-200c were found to be upregulated while miR-100 and miR-125b were insignificantly deregulated. A positive correlation was noted among miR-183, miR-182 and miR-200c and among miR-425-5p, miR-183, miR-200c and miR-21. Further global miRNA microarray profiling studies can aid in finding ethnic specific miRNA biomarkers in the Algerian breast cancer population.
Highlights
Breast cancer is the most common cancer affecting females worldwide, with more than 2 million new cases diagnosed in 2018
The clinical and pathological data of 20 formalin-fixed paraffin-embedded (FFPE) tumor samples taken from Algerian breast cancer patients have been obtained. 75% of the tumor samples are Estrogen Receptor/progesterone receptor positive (ER/PR+) and 55% have a Human Epidermal Growth Factor Receptor 2 positive (HER2+) status. 45% of the samples were from patients above the age of 50
3.2. miRNA expression in breast cancer tissues and normal adjacent tissues miR-21 (p
Summary
Breast cancer is the most common cancer affecting females worldwide, with more than 2 million new cases diagnosed in 2018. In the Middle East and North Africa (MENA) region, breast cancer constitutes 31.1% of the total cancer incidence in females, with a mortality rate of 20.9%. In Algeria, the number of cases diagnosed in 2018 reached 11847, constituting 24% of the cases of cancer incidence among Algerian females in 2018, which is a rate much higher than the rest of the MENA region [1,2]. The median age of diagnosis was found to be 48, and 66% of the diagnosed Algerian females were below the age of 50. There is no available information concerning the severity of the disease in Algeria [3, 4] except that it constituted 13% of the total cancer mortality among the Algerian population in 2018 [2].
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
